Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Moderna’s COVID-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases, says GlobalData

Moderna has announced positive Phase III data for its COVID-19/influenza combination vaccine, mRNA-1083. The investigational combination mRNA vaccine generated statistically significant higher immune responses in relation to the licensed comparator vaccines used in the randomized, observer-blind, active control study among 8,000 adults aged 50 years and older. This development comes less than two weeks after […]
Read more

China leads APAC in institute-led clinical trials, reveals GlobalData

With the evolving landscape of drug development and innovations, several institutes are serving as catalysts by partnering with pharmaceutical companies to drive progress at various stages of research and development. These collaborations are particularly significant in advancing clinical trials, a critical step in drug development. Against this backdrop, within the Asia-Pacific (APAC) region, China leads […]
Read more

BIOSECURE Act forces US pharma to reevaluate China manufacturing reliance, says GlobalData

As the BIOSECURE Act progresses through the US legislative process, the US pharmaceutical industry finds itself at a crossroads. With heavy reliance on Chinese contract manufacturers, US companies are reevaluating their partnerships amidst the proposed regulations aimed at safeguarding national security interests. While the Act remains a topic of debate, some anticipate potential onshoring benefits, […]
Read more

Roche’s Vabysmo further showcases stronghold across wAMD and DME spaces, says GlobalData

Roche has recently presented post-hoc analysis results of the TENAYA (NCT03823287) and LUCERNE (NCT03823300) trials of Vabysmo (faricimab), a VEGF and Ang2 inhibitor, at the Association for Research in Vision and Ophthalmology (ARVO) conference. The data not only showcases Vabysmo’s efficacy in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) but also the […]
Read more

Biosimilar market poised for significant growth in the coming years, says GlobalData

The rise of biologics has revolutionized treatments for traditionally hard-to-treat diseases, leading to the growth of the biosimilar market. As more biologics lose patent protection, the influx of biosimilars is set to expand, offering cost-effective alternatives and significantly impacting their respective markets. This dynamic shift promises broader access to critical therapies, according to GlobalData, a […]
Read more

Biopharmaceutical industry remains mixed over EU reform proposals, finds GlobalData

Reforms to the European Union’s (EU) general pharmaceutical legislation emerge as one of the key policy developments affecting the operating environment for the pharma industry. In a survey, respondents’ opinions on the impact of EU reform proposals were mixed, with the percentage of participants expressing positive, negative, or neutral views remaining varied, according to GlobalData, […]
Read more

IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space, says GlobalData

At this year’s European Renal Association, positive results were presented from Human Immunology Bioscience’s (HI-Bio) interim results of the Phase II IGNAZ clinical trial. According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN). The drug potentially fills an unmet […]
Read more

Neurology remains key therapeutic area for Japan pharma majors, says GlobalData

In the dynamic landscape of healthcare, key neurological disorders like Alzheimer’s disease, epilepsy, Parkinson’s disease, and depression pose significant challenges, particularly in the Asia-Pacific (APAC) region, where prevalence is high. The World Health Organization stated in March 2024 that “over 80% of neurological deaths and health losses occur in low- and middle-income countries, and access […]
Read more

Verona’s Ensifentrine attracts positive opinions in light of anticipated US launch for COPD, says GlobalData

Verona Pharma recently announced that they are finalizing preparations for a potential US launch of Ensifentrine in the third quarter of 2024, depending upon the FDA’s approval, set for June 26, 2024. The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor aims to reduce exacerbations in chronic obstructive pulmonary disease (COPD) patients, administered as a nebulized formulation. […]
Read more

Osteoporosis Awareness & Prevention Month highlights need for prioritizing early diagnosis and advanced treatments, says GlobalData

The Bone Health and Osteoporosis Foundation (BHOF) observes the month of May every year as Osteoporosis Awareness & Prevention Month to shed light on the critical needs of those living with osteoporosis. Advocates emphasize the importance of enhancing education, research, and healthcare strategies to tackle this prevalent, yet frequently neglected condition. Prioritizing prevention, early diagnosis, […]
Read more

Innovent Biologics mazdutide can pave way for transformative T2D treatment, says GlobalData

Innovent Biologics Inc has recently unveiled promising Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. With its potential to revolutionize T2D treatment, mazdutide’s success could not only reshape the landscape of diabetes therapeutics in China but also underscores the growing demand for […]
Read more

Non-injectable medication development remains significant unmet need in female infertility, says GlobalData

Great progress has been made in the management of female infertility since the introduction of assisted reproductive technology, predominantly in vitro fertilization (IVF). However, despite the improvements made in the space, challenges associated with the treatment remain. The development of non-injectable fertility medications represents a significant unmet need, according to key opinion leaders (KOLs) interviewed […]
Read more
1 … 18 19 20 21 22 … 108